Themis Medicare has been granted approval from the Drug Controller General of India (DCGI) for importing and commercialization of Remifentanil 1 mg/2mg Powder for Concentrate for Solution for Injection under the brand name REMITHEM.

The drug has been authorized to be used as an analgesic medication for the induction and maintenance of general anesthesia during both outpatient and inpatient procedures. It’s also approved to be continued as an analgesic throughout the postoperative phase immediately following surgery for adult patients who are under the watch of an anesthesia practitioner within a postoperative care unit or in an intensive care setting.

Additionally, it is approved by the DCGI for use as an analgesic part of monitored anesthesia care in adults.

Remifentanil is a short-acting narcotic analgesic with quick onset and fast offset of the action. It allows for the easy dose titration, exact, and reliable intraoperative control as well as reduced or quickly reversed adverse effects.

The US Food and Drug Administration was the first to approve Remifentanil, which was in the year 1996. Following the approval of the DCGI, the fast acting narcotic painkiller will become available for import by Themis Medicare and marketed in India shortly.

  DCGI, Drug Controller General of India, India, Pain, Remifentanil, REMITHEM, Themis Medicare